Influenza Vaccination Strategies in Patients with Hematologic Cancer

This correspondence presents results from a single-blind, randomized controlled trial evaluating the effectiveness of two doses of adjuvanted versus standard quadrivalent inactivated influenza vaccine (QIV) in patients with hematologic cancers (multiple myeloma, CLL, non-Hodgkin’s lymphoma) who recently received therapy. Among 130 participants, seroconversion rates for different influenza strains were comparable between groups, and the adjuvanted vaccine did not confer superior immunogenicity. Local adverse events were more frequent in the adjuvanted group. These findings suggest limited benefit from intensified vaccination regimens in this population and support annual single-dose QIV use.

This correspondence presents results from a single-blind, randomized controlled trial evaluating the effectiveness of two doses of adjuvanted versus standard quadrivalent inactivated influenza vaccine (QIV) in patients with hematologic cancers (multiple myeloma, CLL, non-Hodgkin’s lymphoma) who recently received therapy. Among 130 participants, seroconversion rates for different influenza strains were comparable between groups, and the adjuvanted vaccine did not confer superior immunogenicity. Local adverse events were more frequent in the adjuvanted group. These findings suggest limited benefit from intensified vaccination regimens in this population and support annual single-dose QIV use.